Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | NAAA | Q02083 | 2/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 6/20 | 0.42 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.42 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.42 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL968142 | 1.00 | MAPK1 (0.55) | MAPK1GAAHTTSMN1; SMN2NAAA | |
| SCHEMBL967534 | 1.00 | MAPK1 (0.55) | MAPK1GAAHTTSMN1; SMN2NAAA | |
| SCHEMBL966084 | 0.99 | MAPK1 (0.53) | MAPK1GAAHTTSMN1; SMN2NAAA | |
| SCHEMBL31580592 | 0.94 | MAPK1 (0.48) | MAPK1GAAHTTSMN1; SMN2NAAA | |
| SCHEMBL791466 | 0.94 | MAPK1 (0.48) | MAPK1GAAHTTSMN1; SMN2NAAA | |
| SCHEMBL7365544 | 0.90 | EPHX1 (0.49) | MAPK1GAAHTTSMN1; SMN2NAAA | |
| SCHEMBL966835 | 0.89 | EPHX1 (0.46) | MAPK1GAAHTTSMN1; SMN2NAAA | |
| SCHEMBL27802851 | 0.87 | NAAA (0.45) | MAPK1GAAHTTSMN1; SMN2NAAA | |
| SCHEMBL27802914 | 0.87 | NAAA (0.45) | MAPK1GAAHTTSMN1; SMN2NAAA | |
| SCHEMBL951710 | 0.86 | GAA (0.50) | MAPK1GAAHTTSMN1; SMN2NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2471775-A1 | Manufacturing method for a piperidine-3-ylcarbamate compound and optical resolution method therefor | SUMITOMO CHEMICAL CO., LTD. (JP) | 2012-07-04 | — | — | EP | disclosed |
| US-20110021780-A1 | MANUFACTURING METHOD FOR A PIPERIDINE-3-YLCARBAMATE COMPOUND AND OPTICAL RESOLUTION METHOD THEREFOR | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-01-27 | — | — | US | disclosed |
| EP-2269986-A1 | MANUFACTURING METHOD FOR A PIPERIDINE-3-YLCARBAMATE COMPOUND AND OPTICAL RESOLUTION METHOD THEREFOR | Sumitomo Chemical Company, Limited (JP) | 2011-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021780-A1 | MANUFACTURING METHOD FOR A PIPERIDINE-3-YLCARBAMATE COMPOUND AND OPTICAL RESOLUTION METHOD THEREFOR | PDCD2L, NOTUM, OXA1L | MAPK1 3124/4885GAA 2447/4885HTT 1801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.